3. A Study of Trastuzumab-MCC-DM1 (T-DM1) in Combination With Pertuzumab Administered to Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
a. ClinicalTrials.gov Identifier: NCT00875979
b. Recruiting; Global
c. Ph I & II
d. Conditions: mBC
e. Interventions: Drug: pertuzumab; Drug: trastuzumab – MCC – DM1